Ionis Pharmaceuticals (IONS) said results from a late-stage study of pelacarsen are expected in H1 2026 after a data readout from the phase 3 trial had been expected from drug development partner Novartis (NVS) this year.
"This update is based on the accrual rate of blinded events in the ongoing Phase 3 Lp(a)HORIZON
event-driven cardiovascular outcomes study that Novartis is conducting in more than 8,000 patients," Ionis said Friday in a statement.
Ionis said the companies expect to seek regulatory approval of the medicine in H2 2026.
"Ionis remains confident in pelacarsen and the Lp(a)HORIZON study and its potential to show benefit in patients with cardiovascular disease and high Lp(a)," according to the statement.
Ionis licensed the drug to Novartis in 2019.
Ionis shares fell 0.8% recent Friday trading, and Novartis rose 0.3%.
Price: 33.06, Change: -0.26, Percent Change: -0.77
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。